[Skip to Content]
[Skip to Content Landing]
April 2007

New Therapies for Ataxia-Telangiectasia—Reply

Author Affiliations

Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2007

Arch Neurol. 2007;64(4):608-609. doi:10.1001/archneur.64.4.608

In reply

We read with interest the letter from Gazulla et al in which they treated a 34-year-old man with AT with a combination of pregabalin (225 mg/d) and tiagabine (7.5 mg/d). The authors reported that pregabalin treatment improved the patient's gait (ie, he could walk more than 10 m without support) and that the addition of tiagabine increased the distance of unsupported walking to more than 20 m and facilitated execution of half turns. The improvements were sustained for an unspecified period after which the beneficial effects of the drugs disappeared and the drugs were withdrawn. Based on their observations, Gazulla et al proposed using pregabalin and tiagabine together rather than betamethasone to treat children with AT in whom we first raised several concerns about adverse effects.1

First Page Preview View Large
First page PDF preview
First page PDF preview